Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU followed by paclitaxel, trastuzumab and pertuzumab, THP, in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback